| Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in … D Khanna, V Nagaraja, C Tseng, F Abtin, R Suh, G Kim, A Wells, DE Furst, ... Arthritis research & therapy 17 (1), 372, 2015 | 119 | 2015 |
| Nasoenteric tube complications S Prabhakaran, VA Doraiswamy, V Nagaraja, J Cipolla, U Ofurum, ... Scandinavian Journal of Surgery 101 (3), 147-155, 2012 | 111 | 2012 |
| Review of abdominal damage control and open abdomens: focus on gastrointestinal complications BP Smith, RC Adams, VA Doraiswamy, V Nagaraja, MJ Seamon, J Wisler, ... J Gastrointestin Liver Dis 19 (4), 425-35, 2010 | 98 | 2010 |
| Management of Gastrointestinal Involvement in Scleroderma V Nagaraja, Z McMahan, T Getzug, D Khanna Current Treatment Options in Rheumatology, 2015 | 92 | 2015 |
| Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled … JJ Solomon, SK Danoff, FA Woodhead, S Hurwitz, R Maurer, I Glaspole, ... The Lancet Respiratory Medicine 11 (1), 87-96, 2023 | 77 | 2023 |
| Measuring response in the gastrointestinal tract in systemic sclerosis D Khanna, V Nagaraja, H Gladue, W Chey, M Pimentel, T Frech Current opinion in rheumatology 25 (6), 700-706, 2013 | 74 | 2013 |
| Old medications and new targeted therapies in systemic sclerosis V Nagaraja, CP Denton, D Khanna Rheumatology 54 (11), 1944-1953, 2015 | 61 | 2015 |
| Establishing clinical severity for PROMIS® measures in adult patients with rheumatic diseases V Nagaraja, C Mara, PP Khanna, R Namas, A Young, DA Fox, T Laing, ... Quality of Life Research 27, 755-764, 2018 | 55 | 2018 |
| Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension A Young, V Nagaraja, M Basilious, M Habib, W Townsend, H Gladue, ... Seminars in arthritis and rheumatism 48 (6), 1059-1067, 2019 | 46 | 2019 |
| Rheumatoid arthritis–associated interstitial lung disease: current update on prevalence, risk factors, and pharmacologic treatment S Huang, VL Kronzer, PF Dellaripa, KD Deane, MB Bolster, V Nagaraja, ... Current treatment options in rheumatology 6, 337-353, 2020 | 45 | 2020 |
| Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective … S Jaafar, A Lescoat, S Huang, J Gordon, M Hinchcliff, AA Shah, S Assassi, ... Arthritis research & therapy 23 (1), 170, 2021 | 40 | 2021 |
| Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial L Chung, C Spino, R McLain, SR Johnson, CP Denton, JA Molitor, ... The Lancet Rheumatology 2 (12), e743-e753, 2020 | 38 | 2020 |
| Current and future outlook on disease modification and defining low disease activity in systemic sclerosis V Nagaraja, M Matucci‐Cerinic, DE Furst, M Kuwana, Y Allanore, ... Arthritis & rheumatology 72 (7), 1049-1058, 2020 | 37 | 2020 |
| Management of scleroderma renal crisis V Nagaraja Current opinion in rheumatology 31 (3), 223-230, 2019 | 32 | 2019 |
| Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis-Results of Phase I/II Investigator-Initiated, Double-Blind Randomized Placebo-Controlled Trial D Khanna, E Bush, V Nagaraja, A Koenig, P Khanna, A Young, J Moore, ... Arthritis & rheumatology 71, 2019 | 29 | 2019 |
| Multidisciplinary evaluation in patients with lung disease associated with connective tissue disease A Wells, A Devaraj, EA Renzoni, CP Denton Seminars in respiratory and critical care medicine 40 (02), 184-193, 2019 | 29 | 2019 |
| Construct validity of the Patient‐Reported Outcomes Measurement Information System gastrointestinal symptom scales in systemic sclerosis V Nagaraja, RD Hays, PP Khanna, BMR Spiegel, L Chang, GY Melmed, ... Arthritis care & research 66 (11), 1725-1730, 2014 | 27 | 2014 |
| Performance of the DETECT algorithm for pulmonary hypertension screening in a systemic sclerosis cohort A Young, VM Moles, S Jaafar, S Visovatti, S Huang, D Vummidi, ... Arthritis & Rheumatology 73 (9), 1731-1737, 2021 | 26 | 2021 |
| A multicenter randomized, double-blind, placebo-controlled pilot study to assess the efficacy and safety of riociguat in systemic sclerosis-associated digital ulcers V Nagaraja, C Spino, E Bush, PS Tsou, RT Domsic, R Lafyatis, T Frech, ... Arthritis Research & Therapy 21, 1-14, 2019 | 26 | 2019 |
| Tofacitinib blocks IFN-regulated biomarker genes in skin fibroblasts and keratinocytes in a systemic sclerosis trial D Khanna, C Padilla, LC Tsoi, V Nagaraja, PP Khanna, T Tabib, ... JCI insight 7 (17), 2022 | 24 | 2022 |
